493 related articles for article (PubMed ID: 27023044)
1. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
Kim JJ; Wright TC; Goldie SJ
JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
[TBL] [Abstract][Full Text] [Related]
4. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
[TBL] [Abstract][Full Text] [Related]
8. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ; Wright TC; Goldie SJ
J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Kim JJ; Ortendahl J; Goldie SJ
Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
[TBL] [Abstract][Full Text] [Related]
13. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
Petry KU; Barth C; Wasem J; Neumann A
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
[TBL] [Abstract][Full Text] [Related]
14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
15. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).
Kulasingam SL; Kim JJ; Lawrence WF; Mandelblatt JS; Myers ER; Schiffman M; Solomon D; Goldie SJ;
J Natl Cancer Inst; 2006 Jan; 98(2):92-100. PubMed ID: 16418511
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
[TBL] [Abstract][Full Text] [Related]
20. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]